StocksFundsScreenerSectorsWatchlists
TEVA

TEVA - Teva Pharmaceutical Industries Ltd Stock Price, Fair Value and News

12.95USD+0.17 (+1.33%)Delayed as of 19 Apr 2024, 11:19 am ET

Market Summary

TEVA
USD12.95+0.17
Delayedas of 19 Apr 2024, 11:19 am
1.33%

TEVA Stock Price

View Fullscreen

TEVA RSI Chart

TEVA Valuation

Market Cap

14.3B

Price/Earnings (Trailing)

-24.85

Price/Sales (Trailing)

0.9

EV/EBITDA

6.97

Price/Free Cashflow

10.45

TEVA Price/Sales (Trailing)

TEVA Profitability

EBT Margin

-4.05%

Return on Equity

-7.67%

Return on Assets

-1.32%

Free Cashflow Yield

9.57%

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

15.8B

Rev. Growth (Yr)

14.77%

Rev. Growth (Qtr)

15.77%

TEVA Earnings

Earnings (TTM)

-575.5M

Earnings Growth (Yr)

134.24%

Earnings Growth (Qtr)

536.43%

Breaking Down TEVA Revenue

52 Week Range

7.0912.99
(Low)(High)

Last 7 days

-7.9%

Last 30 days

-4.3%

Last 90 days

14.3%

Trailing 12 Months

50.5%

How does TEVA drawdown profile look like?

TEVA Financial Health

Current Ratio

1.02

TEVA Investor Care

Shares Dilution (1Y)

0.81%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202314.9B15.0B15.3B15.8B
202215.6B15.4B15.1B14.9B
202116.3B16.3B16.2B15.9B
202017.1B16.8B16.7B16.7B
201917.5B17.1B16.8B16.9B
201821.7B20.5B19.3B18.3B
201722.7B23.4B23.5B22.4B
201619.5B19.6B20.3B21.9B
201520.3B20.2B19.9B19.7B
201420.4B20.5B20.5B20.3B
201320.2B20.1B20.2B20.3B
201219.2B20.0B20.6B20.3B
201116.5B17.0B17.1B18.3B
201016.6B17.0B17.7B16.1B
200911.7B12.2B12.9B16.1B
20089.8B10.2B10.7B11.1B
20070009.4B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Teva Pharmaceutical Industries Ltd

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 06, 2024
kalif eliyahu sharon
sold
-1,048,120
13.5154
-77,550
evp, chief financial officer
Mar 05, 2024
daniell richard
acquired
-
-
77,802
exec. vp, european commercial
Mar 05, 2024
conway vikki l
acquired
-
-
4,954
see remarks
Mar 05, 2024
weiss amir
acquired
-
-
3,564
chief accounting officer
Mar 05, 2024
kalif eliyahu sharon
acquired
-
-
73,707
evp, chief financial officer
Mar 05, 2024
drape eric
acquired
-
-
77,802
executive vp global operations
Mar 05, 2024
sabag mark
sold
-1,352,090
13.5209
-100,000
evp, international markets
Mar 05, 2024
conway vikki l
sold
-19,286
13.5154
-1,427
see remarks
Mar 05, 2024
daniell richard
sold
-657,240
13.5154
-48,629
exec. vp, european commercial
Mar 05, 2024
sabag mark
acquired
-
-
81,897
evp, international markets

1–10 of 50

Which funds bought or sold TEVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
HARTFORD INVESTMENT MANAGEMENT CO
added
0.1
38,019
145,770
-%
Apr 17, 2024
Hennion & Walsh Asset Management, Inc.
added
30.31
1,257,250
2,908,950
0.16%
Apr 17, 2024
Coston, McIsaac & Partners
unchanged
-
3,000
10,000
-%
Apr 16, 2024
Arlington Trust Co LLC
sold off
-100
-2,234
-
-%
Apr 16, 2024
Register Financial Advisors LLC
new
-
409
409
-%
Apr 16, 2024
WEBSTER BANK, N. A.
unchanged
-
642
2,469
-%
Apr 16, 2024
TSFG, LLC
unchanged
-
1,000
3,000
-%
Apr 15, 2024
JANICZEK WEALTH MANAGEMENT, LLC
sold off
-100
-1,232
-
-%
Apr 15, 2024
ATLAS CAPITAL ADVISORS LLC
added
3,427
604,254
617,199
0.10%
Apr 15, 2024
Sound Income Strategies, LLC
unchanged
-
279
1,072
-%

1–10 of 46

Are Funds Buying or Selling TEVA?

Are funds buying TEVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TEVA
No. of Funds

Unveiling Teva Pharmaceutical Industries Ltd's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 09, 2024
phoenix holdings ltd.
4.83%
54,144,997
SC 13G/A
Feb 01, 2024
phoenix holdings ltd.
5.40%
60,522,178
SC 13G
Jun 09, 2023
capital research global investors
0.0%
0
SC 13G/A
Feb 13, 2023
capital research global investors
10.3%
114,793,989
SC 13G/A
Feb 11, 2022
capital research global investors
12.0%
132,350,750
SC 13G/A
Feb 16, 2021
capital research global investors
11.9%
130,140,247
SC 13G/A
Feb 03, 2021
wellington management group llp
0.03%
310,793
SC 13G/A
Feb 14, 2020
capital research global investors
11.9%
130,950,677
SC 13G/A
Feb 05, 2020
franklin resources inc
1.8%
19,916,016
SC 13G/A
Jan 28, 2020
wellington management group llp
7.43%
81,123,996
SC 13G

Recent SEC filings of Teva Pharmaceutical Industries Ltd

View All Filings
Date Filed Form Type Document
Apr 18, 2024
8-K
Current Report
Apr 16, 2024
ARS
ARS
Apr 16, 2024
DEF 14A
DEF 14A
Apr 16, 2024
DEFA14A
DEFA14A
Apr 09, 2024
SC 13G/A
Major Ownership Report
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading

Peers (Alternatives to Teva Pharmaceutical Industries Ltd)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
351.1B
85.2B
-6.70% -10.33%
9.99
4.12
6.46% 95.94%
317.1B
60.1B
2.45% 9.70%
868.73
5.27
1.40% -97.49%
143.3B
46.5B
-8.14% -36.93%
-103.22
3.08
42.59% -114.62%
140.8B
28.2B
-3.32% 6.70%
20.96
4.99
7.09% 2.52%
82.4B
27.1B
-9.93% -21.39%
14.54
3.04
-0.60% 23.36%
14.3B
15.8B
-4.27% 50.53%
-24.85
0.9
6.17% 76.47%
MID-CAP
4.1B
4.7B
-0.96% -17.31%
-319.48
0.87
4.58% 90.97%
4.0B
1.7B
-14.12% -18.81%
11.16
2.39
49.61% 324.78%
3.1B
8.8B
-9.85% 14.21%
-5.31
0.36
7.79% -163.11%
1.9B
644.4M
-13.30% -10.60%
13.51
2.88
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-9.90% -28.22%
-3.8
1.8
24.65% 80.36%
21.7M
1.3M
-17.90% -49.05%
-2.11
16.65
-98.14% -109.18%
17.6M
-
-9.57% 32.48%
-0.96
0.22
2882.68% -138.52%
2.5M
19.6M
-30.19% -94.45%
-0.18
0.13
80.00% 43.08%
472.0K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Teva Pharmaceutical Industries Ltd News

Latest updates
Defense World8 hours ago
The Jerusalem Post16 Apr 202406:38 pm

Teva Pharmaceutical Industries Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue15.8%4,457,000,0003,850,000,0003,878,000,0003,661,000,0003,883,500,0003,595,000,0003,786,000,0003,661,000,0004,099,500,0003,887,000,0003,910,000,0003,982,000,0004,454,000,0003,978,000,0003,870,000,0004,357,000,0004,468,000,0004,093,000,0004,177,000,0004,149,000,0004,419,000,000
Gross Profit30.5%2,415,500,0001,851,000,0001,796,000,0001,582,000,0001,770,000,0001,669,000,0001,794,000,0001,740,000,0002,049,500,0001,794,000,0001,873,000,0001,878,000,0002,048,000,0001,852,000,0001,763,000,0002,063,000,0001,958,000,0001,830,000,0001,893,000,0001,856,000,0001,971,000,000
  S&GA Expenses6.0%610,500,000576,000,000603,000,000546,000,000548,500,000539,000,000594,000,000584,000,000631,500,000597,000,000615,000,000585,000,000683,000,000605,000,000597,000,000613,000,000705,500,000595,000,000666,000,000648,000,000797,000,000
  R&D Expenses---------------------60,000,000
EBITDA Margin-0.10-0.00-0.01-0.060.010.020.110.180.20-0.10-0.11-0.12-0.130.120.080.08-0.13-0.12-0.080.00
Income Taxes437.5%40,500,000-12,000,000-16,000,000-19,000,000149,000,000107,000,000-900,000,0002,000,000-24,500,00076,000,00098,000,00062,000,000-21,000,00016,000,000-104,000,000-59,000,000-119,000,00011,000,000-179,000,0009,000,000-139,000,000
Earnings Before Taxes665.6%490,000,00064,000,000-923,000,000-272,000,000-1,185,000,000171,000,000-1,178,000,000-971,000,000-175,500,000382,000,000308,000,000144,000,000137,000,000-4,459,000,000-51,000,000-33,000,000-39,000,000-292,000,000-850,000,000-84,000,000-3,387,000,000
EBT Margin73.3%-0.04-0.15-0.15-0.16-0.21-0.14-0.12-0.030.040.06-0.24-0.26-0.26-0.27-0.02-0.07-0.07-0.27-0.26-0.22-0.14
Net Income536.4%445,500,00070,000,000-871,000,000-220,000,000-1,301,000,00061,000,000-251,000,000-955,000,000-159,000,000292,000,000207,000,00077,000,000150,000,000-4,349,000,000140,000,00069,000,000110,000,000-314,000,000-689,000,000-105,000,000-2,886,000,000
Net Income Margin76.1%-0.04-0.15-0.15-0.11-0.16-0.09-0.07-0.040.030.04-0.24-0.24-0.24-0.240.00-0.05-0.06-0.24-0.23-0.19-0.12
Free Cashflow23580.0%1,184,000,0005,000,000205,000,000-284,000,000831,000,000421,000,000-4,000,000-206,000,000303,000,000383,000,000105,000,000-555,000,000155,000,000164,000,000142,000,000177,000,000419,000,000156,000,000-339,000,000-13,000,000154,000,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.3%43,47942,09543,10043,46144,01144,25245,93247,05947,66647,85149,19549,00450,64049,73754,99155,33057,47057,24659,42459,85460,683
  Current Assets9.3%12,48511,42512,08811,50112,05111,45312,16412,45112,57312,15412,82212,40113,00512,16012,78112,88413,46412,54213,80513,43113,794
    Cash Equivalents43.4%3,2262,2492,6702,1762,8012,2252,0912,2502,1652,0452,4361,7432,1771,8272,4021,8041,9751,2412,1651,9731,782
  Inventory-0.7%4,0214,0514,1094,1183,8333,8594,0494,0123,8184,1674,3624,4064,4034,5164,3614,2904,4224,6364,8504,7824,731
  Net PPE2.3%5,7505,6225,7125,7515,7395,5685,7405,9325,9826,0406,1276,1126,2966,1526,1226,2216,4366,6436,7326,7856,868
  Goodwill1.7%17,17716,88517,11817,79917,63318,43318,83719,98620,04020,17920,42120,30220,62420,22824,61624,49024,84624,65724,91324,82224,917
Liabilities1.9%35,35334,70835,50834,95735,41334,74736,12136,79936,42236,40037,88438,02939,57939,14540,16740,74242,40742,32244,17344,03344,889
  Current Liabilities7.5%12,24711,39411,84310,41111,46911,53410,99611,61311,02711,82512,69112,08913,16412,10311,75112,32213,67414,10714,45214,02814,322
Shareholder's Equity1.6%7,5067,3877,5928,5047,8049,5069,81010,26011,24411,45111,31110,97511,06110,59214,82414,58815,06314,92515,25115,82115,794
  Retained Earnings3.3%-13,534-13,995-14,066-13,194-12,975-11,673-11,734-11,484-10,529-10,370-10,662-10,869-10,946-11,096-6,747-6,887-6,956-7,066-6,752-6,063-5,958
  Additional Paid-In Capital0.1%27,80727,78027,74827,71927,68827,65227,62527,58727,56127,52927,50327,47427,44327,40327,37427,34227,31227,29327,25827,23427,210
Shares Outstanding-0.2%1,1191,1211,1201,1151,1101,1111,1101,1071,1021,1031,1011,0991,0951,0961,0961,0931,0911,0911,0911,0901,021
Minority Interest6.5%6205826567517947517919169669849879751,0359999721,0571,0911,1341,1281,0891,087
Float---8,380---7,300---9,550---11,830---8,820--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations23580.0%1,1845.00324-145973543123-49.00456529218-405331307273305538325-227112367
  Share Based Compensation-9.7%28.0031.0030.0032.0036.0026.0039.0024.0033.0026.0029.0031.0038.0029.0032.0030.0020.0035.0030.0034.0033.00
Cashflow From Investing63.6%30118430218116914717916124628848150814115731325243022442927274.00
Cashflow From Financing0%-576-576-55.00-706-711-439-3382.00-501-1,177-1.00-493-125-1,057-3.00-700-241-1,461-35.00-189-499
  Dividend Payments----------------------

TEVA Income Statement

2023-12-31
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Net revenues$ 15,846$ 14,925$ 15,878
Cost of sales8,2007,9528,284
Gross profit7,6456,9737,594
Research and development expenses, net953838967
Selling and marketing expenses2,3362,2652,429
General and administrative expenses1,1621,1801,099
Intangible assets impairments350355424
Goodwill impairment7002,0450
Other asset impairments, restructuring and other items[1]718512341
Legal settlements and loss contingencies1,0432,082717
Other income(49)(107)(98)
Operating (loss) income[1]433(2,197)1,716
Financial expenses – net1,0579661,058
Income (loss) before income taxes[1],[2](624)(3,163)658
Income taxes (benefit)[2](7)(643)211
Share in (profits) losses of associated companies – net(2)(21)(9)
Net income (loss)(615)(2,499)456
Net income (loss) attributable to non-controlling interests(56)(53)39
Net income (loss) attributable to Teva$ (559)$ (2,446)$ 417
Earnings (loss) per share attributable to ordinary shareholders:   
Basic$ (0.5)$ (2.2)$ 0.38
Diluted$ (0.5)$ (2.2)$ 0.38
Weighted average number of shares (in millions):   
Basic1,1191,1101,102
Diluted1,1191,1101,107
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

TEVA Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,226$ 2,801
Accounts receivables, net of allowance for credit losses of $95 million and $91 million as of December 31, 2023 and December 31, 2022, respectively3,4083,696
Inventories4,0213,833
Prepaid expenses1,2551,162
Other current assets504549
Assets held for sale7010
Total current assets12,48512,051
Deferred income taxes1,8121,458
Other non-current assets470441
Property, plant and equipment, net5,7505,739
Operating lease right-of-use assets397419
Identifiable intangible assets, net5,3876,270
Goodwill[1]17,17717,633
Total assets43,47944,011
Current liabilities:  
Short-term debt1,6722,109
Sales reserves and allowances3,5353,750
Accounts payables2,6021,887
Employee-related obligations611566
Accrued expenses2,7712,151
Other current liabilities1,0561,005
Total current liabilities12,24711,469
Long-term liabilities:  
Deferred income taxes606548
Other taxes and long-term liabilities4,0193,945
Senior notes and loans18,16119,103
Operating lease liabilities320349
Total long-term liabilities23,10623,944
Commitments and contingencies, see note 12 
Total liabilities35,35335,413
Teva shareholders' equity:  
Ordinary shares of NIS 0.10 par value per share; December 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively5757
Additional paid-in capital27,80727,688
Accumulated deficit(13,534)(12,975)
Accumulated other comprehensive loss(2,697)(2,838)
Treasury shares as of December 31, 2023 and December 31, 2022: 106 million ordinary shares(4,128)(4,128)
Stockholders' equity attributable to Teva shareholders7,5067,804
Non-controlling interests620794
Total equity8,1268,598
Total liabilities and equity$ 43,479$ 44,011
[1]Cumulative goodwill impairment as of December 31, 2023, December 31, 2022 and December 31, 2021 was approximately $28.3 billion, $27.6 billion and $25.6 billion respectively.
TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
 CEO
 WEBSITEtevapharm.com
 INDUSTRYPharmaceuticals
 EMPLOYEES34004

Teva Pharmaceutical Industries Ltd Frequently Asked Questions


What is the ticker symbol for Teva Pharmaceutical Industries Ltd? What does TEVA stand for in stocks?

TEVA is the stock ticker symbol of Teva Pharmaceutical Industries Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Teva Pharmaceutical Industries Ltd (TEVA)?

As of Thu Apr 18 2024, market cap of Teva Pharmaceutical Industries Ltd is 14.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TEVA stock?

You can check TEVA's fair value in chart for subscribers.

What is the fair value of TEVA stock?

You can check TEVA's fair value in chart for subscribers. The fair value of Teva Pharmaceutical Industries Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Teva Pharmaceutical Industries Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TEVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Teva Pharmaceutical Industries Ltd a good stock to buy?

The fair value guage provides a quick view whether TEVA is over valued or under valued. Whether Teva Pharmaceutical Industries Ltd is cheap or expensive depends on the assumptions which impact Teva Pharmaceutical Industries Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TEVA.

What is Teva Pharmaceutical Industries Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, TEVA's PE ratio (Price to Earnings) is -24.85 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TEVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Teva Pharmaceutical Industries Ltd's stock?

In the past 10 years, Teva Pharmaceutical Industries Ltd has provided -0.12 (multiply by 100 for percentage) rate of return.